CVS will close 270 more stores by 2025 to streamline operations, sparking concerns over reduced pharmacy access in vulnerable ...

CVS is reportedly offering staff rewards like bonuses and pizza parties to increase vaccination rates, amid slowing demand ...

The company’s new transformation strategy, called Celebrations Wave, aims to increase revenues across both every day and holiday occasions, optimize operations, lower costs and accelerate the pace of ...

A two-part communication strategy that included discussing vaccine concerns with skeptical parents was not effective in boosting immunization among their children, according to a new study ...

Management reaffirmed 2025 guidance for net sales growth of 3% to 5% and adjusted diluted EPS in the range of $7.55 to $7.85. This guidance does not factor in potential impacts from new tariffs or ...

While sales of its COVID-19 vaccine continue to decline as expected in a post-pandemic market, Moderna is taking proactive steps to reshape its future. The company is swiftly advancing multiple ...

The only segment to decline was commercial vehicles, where sales dropped by 1.05% to 90,558 ... Nonetheless, the bus segment within CVs remained strong, fuelled by institutional demand from ...

PPG reports that its Performance Coatings segment Q1 organic sales increased by 9% with price and sales volume improvements. Chairman and CEO Tim Kenevich said during the company’s Q1 earnings ...

The company reported its steepest U.S. sales decline since 2020 ... This pivot aligns with a broader strategy announced earlier this year. McDonald’s formed new global “Category Management” teams ...

CVS Health's retail business overall looks good for 2025, Joyner said, adding a "caution" relating to vaccines and immunization. This week the Trump administration asked for a new clinical trial ...

Same-Store Pharmacy Sales Growth: Nearly 18% versus the ... supply chain and consumer sentiment towards vaccines could affect CVS Health Corp (NYSE:CVS)'s operations and financial performance.

Danish drugmaker Novo Nordisk (NOV: N) has secured a significant advantage in the high-stakes obesity drug market after landing a new formulary deal with US pharmacy benefits giant CVS Health (NYSE: ...